Sign in
Stories
Securities Fraud Lawsuits Against bluebird bio
Share
Securities Fraud Lawsuits Against bluebi...
AMYLYX PHARMACEUTICALS Lawsuit Deadline ...
AVXL Lawsuit Roils Investors
AVXL Lawsuit: Deceptive Practices Expose...
Overview
API
Multiple law firms have initiated class action lawsuits against bluebird bio, Inc. for allegedly making false statements about FDA approvals, resulting in significant stock price drops. The lawsuits claim misleading statements about gene therapy drugs for sickle cell disease and violations of securities laws, leading to investor damages.
Ask a question
Are there regulatory changes needed to prevent similar instances of alleged false statements in the future?
How might these lawsuits impact bluebird bio, Inc.'s reputation within the pharmaceutical industry?
What measures can companies take to ensure accurate and transparent communication with investors and regulatory bodies?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Mar 2024
Coverage